RxDoctor Payments Data

Hamid Burney, MD

Internal Medicine · Arlington, TXNPI 1134125453

Payments from drug & device makers

$542in general payments, 2019–2025

Across 27 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$124
  • Novo Nordisk$114
  • Bayer$68
  • Astellas Pharma US Inc$65
  • Exact Sciences$54
  • Amgen$42
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$47788%
  • Education$6512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$542 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$138,437
Medicare patients
257
Services billed
1,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide139$213,290
JardianceEmpagliflozin110$161,646
FarxigaDapagliflozin Propanediol136$159,467
TrulicityDulaglutide105$155,249
OzempicSemaglutide78$119,282
EliquisApixaban62$85,601
RybelsusSemaglutide27$63,720
JanuviaSitagliptin Phosphate42$60,182
LinzessLinaclotide56$58,068
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$57,633
MyrbetriqMirabegron56$50,060
Tresiba Flextouch U-200Insulin Degludec53$38,966
Repatha SureclickEvolocumab33$38,571
XareltoRivaroxaban38$37,947
JanumetSitagliptin Phos/Metformin Hcl33$37,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$124$368,538244 claims
Novo NordiskOzempic, Rybelsus$114$183,001105 claims
GSKTrelegy Ellipta$23$57,63344 claims
Astellas Pharma US IncMyrbetriq$65$50,06056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →